Ubiquitin-activating enzyme 1 (UBA1, also known as UBE1 or UBAE1) is the primary E1 activating enzyme initiating the three-step ubiquitin-proteasome cascade. As a master regulator of cellular protein degradation, cell cycle progression, and DNA damage response, UBA1 has emerged as a high-value therapeutic target in oncology (particularly hematological malignancies like AML and MDS) and autoinflammatory conditions such as VEXAS syndrome.
TarMart Solution Ecosystem & Related Targets
To support robust high-throughput screening (HTS), lead optimization, and selectivity profiling, TarMart provides a complete suite of sequence-verified, high-purity reagents designed to streamline your UBA1 drug discovery workflow.
"Comprehensive reagent toolkit for UBA1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | UBA1 Wild-Type & Mutant (VEXAS-associated) Recombinant Proteins High purity (>95%), Endotoxin Controlled, Sequence Verified. Suitable for enzymatic assays and biophysical binding studies. |
View UBA1 Products |
| Gene Delivery | UBA1 Promise-ORF / Lentivirus Full-length ORF lentiviral particles for stable cell line generation and target engagement assays. |
View UBA1 Products |
| Benchmark Ab | Anti-UBA1 Recombinant Antibody High-affinity positive control for Western Blot, ELISA, and immunofluorescence assays. |
View UBA1 Products |
| Validator | UBA1 siRNA Set Target-specific siRNA pool for gene knockdown and functional validation. |
View UBA1 Products |
| Related Target A | SAE1 (SUMO-Activating Enzyme Subunit 1) Critical for counter-screening to ensure E1 family selectivity. |
View SAE1 Products |
| Related Target B | NAE1 (NEDD8-Activating Enzyme Subunit 1) Essential homolog for selectivity profiling of small-molecule E1 inhibitors. |
View NAE1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| E1 Homolog Selectivity Screening | Highly purified SAE1 and NAE1 proteins available for robust off-target counter-screening panels. |
| VEXAS Mutant Profiling | Custom-designed UBA1 mutant proteins (e.g., M41T, M41V, M41L) with verified primary sequence and high purity. |
| Inconsistent Enzyme Activity | Strictly endotoxin-controlled, native-conformation proteins ensuring reproducible ATP-pyrophosphate exchange kinetics. |
| Lack of Reliable Controls | Sequence-defined clinical-grade benchmark antibodies and validated siRNA sets included for baseline alignment. |
Live UBA1 R&D Tracker
The global competitive landscape for ubiquitin-proteasome system (UPS) inhibitors is evolving rapidly. Stay updated with real-time research, clinical trials, and intellectual property developments:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of UBA1 has transitioned from academic validation to active clinical evaluation. Small-molecule inhibitors of UBA1, such as TAK-243 (MLN7243), have demonstrated profound anti-tumor efficacy by inducing proteotoxic stress, disrupting DNA damage repair, and depleting cellular ubiquitin pools. Clinical development is currently focused on overcoming hematological malignancies and solid tumors refractory to standard proteasome inhibitors (e.g., bortezomib).
Concurrently, the discovery of somatic mutations in the UBA1 gene (specifically at codon Met41) as the clonal driver of VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome has opened a brand new therapeutic frontier. The next wave of R&D is heavily focused on developing mutant-selective UBA1 inhibitors, molecular glues, and PROTACs that can selectively degrade or inhibit mutated UBA1 while sparing wild-type function to mitigate systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors (Pan-E1) | Takeda Pharmaceutical, Millennium | AML, MDS, Solid Tumors | High-throughput enzymatic assays requiring highly active, pure recombinant WT UBA1 protein. |
| Mutant-Selective Inhibitors | Biotech Startups, Academic Consortia | VEXAS Syndrome | Isogenic screening utilizing mutant UBA1 (M41T/V/L) vs. WT UBA1 recombinant proteins. |
| Targeted Protein Degraders (PROTACs) | Arvinas, Kymera Therapeutics | Oncology, Autoimmune | Cellular target engagement assays requiring high-titer Lentivirus for stable reporter cell line generation. |